FIB-4 Score: What It Is, How It's Calculated & What It Means for Your Liver

Quick answer: The FIB-4 score is a simple calculation using age, AST, ALT, and platelet count to estimate the likelihood of significant liver fibrosis (scarring). It was originally developed for hepatitis C and is now used broadly as a non-invasive screening tool for liver fibrosis in the context of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). A score below 1.30 makes significant fibrosis unlikely; a score above 2.67 warrants further clinical evaluation.

What the FIB-4 Score Measures

Liver fibrosis is the accumulation of scar tissue within the liver, typically occurring in response to sustained inflammation or injury. In early stages, fibrosis may produce no symptoms and no abnormalities on standard liver function tests — making non-invasive screening tools particularly valuable. The FIB-4 score was developed as a way to use routinely available blood test data to estimate the probability of clinically significant fibrosis without requiring liver biopsy or advanced imaging.

The score does not confirm fibrosis — it stratifies risk. A low FIB-4 score indicates that advanced fibrosis is unlikely, while a high score indicates that further evaluation (such as liver elastography or biopsy) is warranted. The FIB-4 is not a standalone diagnostic tool; it is a triage and monitoring instrument used in clinical context.

How FIB-4 is Calculated

The formula

The FIB-4 calculation uses four variables that are available from standard blood panels:

FIB-4 = (Age [years] × AST [U/L]) / (Platelet count [10⁹/L] × √ALT [U/L])

For example, a 50-year-old with AST of 45 U/L, ALT of 36 U/L, and a platelet count of 200 × 10⁹/L would have:

FIB-4 = (50 × 45) / (200 × √36) = 2,250 / (200 × 6) = 2,250 / 1,200 = 1.88

This result would fall in the intermediate zone, warranting clinical assessment and potentially additional testing.

What each variable contributes

• Age: Older age is associated with a higher likelihood of significant fibrosis for any given degree of liver inflammation, reflecting the cumulative nature of fibrotic change over time.
• AST (aspartate aminotransferase): An enzyme released when hepatocytes (liver cells) are damaged. Elevated AST reflects hepatocellular injury. In later-stage fibrosis, the AST/ALT ratio tends to rise above 1 as regenerative capacity declines.
• ALT (alanine aminotransferase): A more liver-specific enzyme than AST; elevated ALT is a sensitive indicator of active hepatocellular inflammation.
• Platelet count: As fibrosis advances to cirrhosis, portal hypertension and splenic sequestration reduce platelet count. Falling platelets are therefore an indirect marker of advancing liver disease. A declining platelet count over serial measurements is a particularly informative trend.

Interpreting FIB-4 Results

• <1.30 — Low risk of significant fibrosis (F0–F1); routine monitoring with attention to metabolic risk factors
• 1.30–2.67 — Intermediate, indeterminate zone; clinical assessment recommended, and liver elastography or additional non-invasive tests may be considered
• >2.67 — Elevated risk of advanced fibrosis or cirrhosis (F3–F4); hepatology referral recommended with liver elastography or biopsy for confirmation

Reference cut-offs are based on validation studies in hepatitis C and MASLD populations. In individuals over 65, the FIB-4 score tends to be higher due to the age variable, and some guidelines recommend higher cut-off thresholds for older patients to avoid overcalling risk. Reference ranges and appropriate thresholds vary by clinical context; all results should be interpreted by a qualified provider.

Where FIB-4 is Most Commonly Used

Metabolic dysfunction-associated steatotic liver disease (MASLD)

MASLD (previously called non-alcoholic fatty liver disease or NAFLD) is the most common liver condition in many high-income countries, affecting an estimated 25–38% of adults globally. It ranges from simple hepatic steatosis (fat accumulation without inflammation) to metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) with inflammation and fibrosis, which can progress to cirrhosis and hepatocellular carcinoma. Because most people with MASLD are asymptomatic in early stages, the FIB-4 score provides a non-invasive way to identify individuals who may already have significant fibrosis and require further evaluation.

Multiple clinical guidelines — including those from the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) — endorse the FIB-4 score as a first-line non-invasive test for liver fibrosis assessment in the primary care and general medicine setting.

Monitoring over time

Serial FIB-4 measurements over months to years can track the trajectory of liver health. A stable or declining score alongside metabolic improvements — such as weight reduction, improved HbA1c, and lower triglycerides — suggests that fibrosis risk is being managed. A rising score despite apparently normal liver enzyme levels is a signal for closer evaluation.

Limitations of the FIB-4 Score

The FIB-4 has meaningful limitations. Conditions that independently alter any of its component values can distort the result. Elevated AST from muscle injury, hemolysis, or cardiac sources rather than liver damage will artifactually raise the score. Thrombocytopenia from non-hepatic causes (such as immune thrombocytopenia or chemotherapy) will similarly inflate it. The score performs best in populations with a meaningful prevalence of liver disease; in very low-risk populations, positive predictive value decreases. It is also poorly validated in pediatric populations and in individuals with certain viral infections. Clinicians use FIB-4 as one input, not the sole determinant of liver health assessment.

Biomarkers Needed to Calculate FIB-4

• AST — Liver enzyme; reflects hepatocellular injury
• ALT — Liver enzyme; liver-specific marker of inflammation
• Platelet count — Declines with advancing fibrosis and portal hypertension. Included in the Baseline Blood Panel CBC
• Age — Input variable incorporated into the formula directly

All four inputs needed to calculate a FIB-4 score — AST, ALT, and platelet count — are included in Superpower's Baseline Blood Panel. Metabolic context markers that inform liver health in a broader sense — including fasting glucose, HbA1c, triglycerides, and fasting insulin — are also part of the standard panel.